Legend Biotech Grows Revenue 51.9% but Trades Near Its Two-Year Low as Net Losses Linger

Legend Biotech, the developer of the CAR-T cell therapy Carvykti for multiple myeloma, which it sells in partnership with Johnson & Johnson, is growing fast. Yahoo Finance data shows trailing revenue up 51.9% to $1.3 billion and a positive operating margin of 14.9%. Yet the company still reports a net loss, with earnings per share of -$0.52, and the stock sits close to the bottom of its two-year range. This Legend Biotech stock analysis, based on Yahoo Finance data as of October 15, 2026, explains why the scoring model rates the shares a Hold, and why the risks of a single-product biotech deserve as much attention as the growth.

What Is Happening With the Stock Price

Legend Biotech trades at $19.04, for a market value of $3.70 billion. The shares were among the biggest one-day gainers on our watchlist, but the move does little to change the bigger picture. The two-year range runs from $16.80 to $44.74, which places the stock at the lower end of that range: about 13% above the low and about 57% below the high. The company also sold new shares in a public offering in June, adding to the share count. A price this close to the low despite rapid sales growth suggests investors are focused on how long it will take to reach steady profits.

Quality: Is This a Financially Sound Business?

Quality scores 53/100. The gross margin is 56.6% and the operating margin is a positive 14.9%, but the net margin is -7.2%, return on equity is -8.1% and return on assets is -1.9%. The figures do not fully agree with each other: EV/EBITDA is -66.78, which implies negative trailing EBITDA, while the operating margin is positive. Press coverage of the company’s August results described the second quarter as its first profitable quarter as a whole company, so trailing figures that include earlier loss-making periods may still show losses. The operating margin should be treated with some caution until it holds over a full year.

The balance sheet is a strength in this Legend Biotech stock analysis. Debt-to-equity is 0.23, and a current ratio of 3.04 and quick ratio of 2.88 point to ample liquidity. Free cash flow is just $27 million on $1.3 billion of revenue, so the company is only just generating cash.

Growth: Does This Company Have Real Upside?

Growth scores 93/100, the strongest pillar by far. Trailing revenue growth is 51.9%, and the compound growth rate across the annual statements in the data is 106.4%, reflecting how quickly Carvykti sales have scaled from a small base. Earnings growth is N/A because the company is still loss-making on a net basis. An EV/Revenue multiple of 2.18 is modest for a biotech growing this quickly, which suggests the market doubts how durable that growth is, given competition from other myeloma treatments and reliance on one product and one partner.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores 27/100. The P/E ratio is N/A because earnings are negative, the price-to-book ratio is 3.00 and the free cash flow yield is 0.7%, so conventional valuation measures offer little support yet. A share price at the lower end of its two-year range could look like a contrarian setup, but the model gives price position only a small weight and ties it to business quality, and shares that look cheap can stay cheap if growth slows. The main risks are dependence on a single therapy, a net loss that has not yet turned into steady profit, further share issuance that would dilute existing holders, and the cost and uncertainty of developing new treatments.

Legend Biotech Stock Analysis: The Bottom Line

Our Legend Biotech stock analysis finds a fast-growing company with a strong balance sheet that is still working toward consistent profits, and a share price that has fallen a long way from its two-year high. Quality is 53/100, Growth 93/100 and Opportunity 27/100, for a recommendation score of 58/100 and a Hold signal. That score is below the 60 the model needs for a Buy, and Opportunity at 27/100 is also below the model’s minimum of 30 for a Buy. The bull case is 51.9% revenue growth, a 56.6% gross margin and little debt. The bear case is a -7.2% net margin, EPS of -$0.52, thin free cash flow and the risk of further dilution. For a smaller, single-product biotech, the risks deserve as much weight as the growth. Buy / Hold / Sell reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity), a data-driven signal for further research, not a personalized recommendation to transact.